Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations: I. Quarter-level outcomes

A. G. Arruda, S. Godden, P. Rapnicki, P. Gorden, L. Timms, Sharif S Aly, Terry W Lehenbauer, J. Champagne

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

The study objective was to compare the efficacy of 3 commercial dry cow mastitis formulations regarding quarter-level prevalence of intramammary infections (IMI) postcalving, cure of preexisting infections over the dry period, prevention of new infections during the dry period, and risk for a clinical mastitis case between calving and 100. d in milk (DIM). A total of 1,091 cows (4,364 quarters) from 6 commercial dairy herds in 4 different states (California, Iowa, Minnesota, and Wisconsin) were enrolled and randomized to 1 of the 3 treatments at dry-off: Quartermaster (QT; 1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal Health, New York, NY), Spectramast DC (SP; 500 mg of ceftiofur hydrochloride; Pfizer Animal Health), or ToMorrow Dry Cow (TM; 300. mg of cephapirin benzathine; Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO). Quarter milk samples were collected for routine bacteriological culture before dry cow therapy treatment at dry-off, 0 to 6 DIM, and 7 to 13 DIM and an on-farm record-keeping system was used to retrieve data on clinical mastitis cases. Noninferiority analysis was used to evaluate the effect of treatment on the primary outcome, risk for a bacteriological cure during the dry period. Multivariable logistic regression techniques were used to describe the effect of treatment on risk for presence of IMI postcalving and risk of a new IMI during the dry period. Cox proportional hazards regression was used to describe the effect of treatment on the risk and time for quarters to experience an episode of clinical mastitis between calving and 100 DIM. The overall crude quarter-level prevalence of infection at dry-off was 19.2%. The most common pathogen isolated from milk samples at dry-off was coagulase-negative Staphylococcus, followed by Aerococcus spp. and other Streptococcus spp. Noninferiority analysis showed no effect of treatment on risk for a cure between dry-off and calving [least squares means (LSM): QT = 93.3%, SP = 92.6%, and TM = 94.0%] and secondary analysis showed no effect of treatment on risk for presence of an IMI at 0 to 6 DIM (LSM: QT = 16.5%, SP = 14.1%, and TM = 16.0%), risk for development of a new IMI between dry-off and 0 to 6 DIM (LSM: QT = 14.8%, SP = 12.3%, and TM = 14.2%), or risk of experiencing a clinical mastitis event between calving and 100 DIM (LSM: QT = 5.3%, SP = 3.8%, and TM = 4.1%). In conclusion, no difference was observed in efficacy among the 3 products evaluated when assessing the aforementioned quarter-level outcomes.

Original languageEnglish (US)
Pages (from-to)4419-4435
Number of pages17
JournalJournal of Dairy Science
Volume96
Issue number7
DOIs
StatePublished - 2013

Fingerprint

randomized clinical trials
Mastitis
mastitis
Milk
Randomized Controlled Trials
cows
milk
dry period (lactation)
Infection
Least-Squares Analysis
infection
calving
least squares
animal health
Aerococcus
Cephapirin
Dihydrostreptomycin Sulfate
Penicillin G Procaine
farm records
cephapirin

Keywords

  • Dry cow mastitis
  • Dry cow therapy
  • Quarter-level outcome

ASJC Scopus subject areas

  • Food Science
  • Animal Science and Zoology
  • Genetics

Cite this

Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations : I. Quarter-level outcomes. / Arruda, A. G.; Godden, S.; Rapnicki, P.; Gorden, P.; Timms, L.; Aly, Sharif S; Lehenbauer, Terry W; Champagne, J.

In: Journal of Dairy Science, Vol. 96, No. 7, 2013, p. 4419-4435.

Research output: Contribution to journalArticle

Arruda, A. G. ; Godden, S. ; Rapnicki, P. ; Gorden, P. ; Timms, L. ; Aly, Sharif S ; Lehenbauer, Terry W ; Champagne, J. / Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations : I. Quarter-level outcomes. In: Journal of Dairy Science. 2013 ; Vol. 96, No. 7. pp. 4419-4435.
@article{5450a8195e68490abbec2bce8127216d,
title = "Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations: I. Quarter-level outcomes",
abstract = "The study objective was to compare the efficacy of 3 commercial dry cow mastitis formulations regarding quarter-level prevalence of intramammary infections (IMI) postcalving, cure of preexisting infections over the dry period, prevention of new infections during the dry period, and risk for a clinical mastitis case between calving and 100. d in milk (DIM). A total of 1,091 cows (4,364 quarters) from 6 commercial dairy herds in 4 different states (California, Iowa, Minnesota, and Wisconsin) were enrolled and randomized to 1 of the 3 treatments at dry-off: Quartermaster (QT; 1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal Health, New York, NY), Spectramast DC (SP; 500 mg of ceftiofur hydrochloride; Pfizer Animal Health), or ToMorrow Dry Cow (TM; 300. mg of cephapirin benzathine; Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO). Quarter milk samples were collected for routine bacteriological culture before dry cow therapy treatment at dry-off, 0 to 6 DIM, and 7 to 13 DIM and an on-farm record-keeping system was used to retrieve data on clinical mastitis cases. Noninferiority analysis was used to evaluate the effect of treatment on the primary outcome, risk for a bacteriological cure during the dry period. Multivariable logistic regression techniques were used to describe the effect of treatment on risk for presence of IMI postcalving and risk of a new IMI during the dry period. Cox proportional hazards regression was used to describe the effect of treatment on the risk and time for quarters to experience an episode of clinical mastitis between calving and 100 DIM. The overall crude quarter-level prevalence of infection at dry-off was 19.2{\%}. The most common pathogen isolated from milk samples at dry-off was coagulase-negative Staphylococcus, followed by Aerococcus spp. and other Streptococcus spp. Noninferiority analysis showed no effect of treatment on risk for a cure between dry-off and calving [least squares means (LSM): QT = 93.3{\%}, SP = 92.6{\%}, and TM = 94.0{\%}] and secondary analysis showed no effect of treatment on risk for presence of an IMI at 0 to 6 DIM (LSM: QT = 16.5{\%}, SP = 14.1{\%}, and TM = 16.0{\%}), risk for development of a new IMI between dry-off and 0 to 6 DIM (LSM: QT = 14.8{\%}, SP = 12.3{\%}, and TM = 14.2{\%}), or risk of experiencing a clinical mastitis event between calving and 100 DIM (LSM: QT = 5.3{\%}, SP = 3.8{\%}, and TM = 4.1{\%}). In conclusion, no difference was observed in efficacy among the 3 products evaluated when assessing the aforementioned quarter-level outcomes.",
keywords = "Dry cow mastitis, Dry cow therapy, Quarter-level outcome",
author = "Arruda, {A. G.} and S. Godden and P. Rapnicki and P. Gorden and L. Timms and Aly, {Sharif S} and Lehenbauer, {Terry W} and J. Champagne",
year = "2013",
doi = "10.3168/jds.",
language = "English (US)",
volume = "96",
pages = "4419--4435",
journal = "Journal of Dairy Science",
issn = "0022-0302",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Randomized noninferiority clinical trial evaluating 3 commercial dry cow mastitis preparations

T2 - I. Quarter-level outcomes

AU - Arruda, A. G.

AU - Godden, S.

AU - Rapnicki, P.

AU - Gorden, P.

AU - Timms, L.

AU - Aly, Sharif S

AU - Lehenbauer, Terry W

AU - Champagne, J.

PY - 2013

Y1 - 2013

N2 - The study objective was to compare the efficacy of 3 commercial dry cow mastitis formulations regarding quarter-level prevalence of intramammary infections (IMI) postcalving, cure of preexisting infections over the dry period, prevention of new infections during the dry period, and risk for a clinical mastitis case between calving and 100. d in milk (DIM). A total of 1,091 cows (4,364 quarters) from 6 commercial dairy herds in 4 different states (California, Iowa, Minnesota, and Wisconsin) were enrolled and randomized to 1 of the 3 treatments at dry-off: Quartermaster (QT; 1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal Health, New York, NY), Spectramast DC (SP; 500 mg of ceftiofur hydrochloride; Pfizer Animal Health), or ToMorrow Dry Cow (TM; 300. mg of cephapirin benzathine; Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO). Quarter milk samples were collected for routine bacteriological culture before dry cow therapy treatment at dry-off, 0 to 6 DIM, and 7 to 13 DIM and an on-farm record-keeping system was used to retrieve data on clinical mastitis cases. Noninferiority analysis was used to evaluate the effect of treatment on the primary outcome, risk for a bacteriological cure during the dry period. Multivariable logistic regression techniques were used to describe the effect of treatment on risk for presence of IMI postcalving and risk of a new IMI during the dry period. Cox proportional hazards regression was used to describe the effect of treatment on the risk and time for quarters to experience an episode of clinical mastitis between calving and 100 DIM. The overall crude quarter-level prevalence of infection at dry-off was 19.2%. The most common pathogen isolated from milk samples at dry-off was coagulase-negative Staphylococcus, followed by Aerococcus spp. and other Streptococcus spp. Noninferiority analysis showed no effect of treatment on risk for a cure between dry-off and calving [least squares means (LSM): QT = 93.3%, SP = 92.6%, and TM = 94.0%] and secondary analysis showed no effect of treatment on risk for presence of an IMI at 0 to 6 DIM (LSM: QT = 16.5%, SP = 14.1%, and TM = 16.0%), risk for development of a new IMI between dry-off and 0 to 6 DIM (LSM: QT = 14.8%, SP = 12.3%, and TM = 14.2%), or risk of experiencing a clinical mastitis event between calving and 100 DIM (LSM: QT = 5.3%, SP = 3.8%, and TM = 4.1%). In conclusion, no difference was observed in efficacy among the 3 products evaluated when assessing the aforementioned quarter-level outcomes.

AB - The study objective was to compare the efficacy of 3 commercial dry cow mastitis formulations regarding quarter-level prevalence of intramammary infections (IMI) postcalving, cure of preexisting infections over the dry period, prevention of new infections during the dry period, and risk for a clinical mastitis case between calving and 100. d in milk (DIM). A total of 1,091 cows (4,364 quarters) from 6 commercial dairy herds in 4 different states (California, Iowa, Minnesota, and Wisconsin) were enrolled and randomized to 1 of the 3 treatments at dry-off: Quartermaster (QT; 1,000,000 IU of procaine penicillin G and 1 g of dihydrostreptomycin; Pfizer Animal Health, New York, NY), Spectramast DC (SP; 500 mg of ceftiofur hydrochloride; Pfizer Animal Health), or ToMorrow Dry Cow (TM; 300. mg of cephapirin benzathine; Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO). Quarter milk samples were collected for routine bacteriological culture before dry cow therapy treatment at dry-off, 0 to 6 DIM, and 7 to 13 DIM and an on-farm record-keeping system was used to retrieve data on clinical mastitis cases. Noninferiority analysis was used to evaluate the effect of treatment on the primary outcome, risk for a bacteriological cure during the dry period. Multivariable logistic regression techniques were used to describe the effect of treatment on risk for presence of IMI postcalving and risk of a new IMI during the dry period. Cox proportional hazards regression was used to describe the effect of treatment on the risk and time for quarters to experience an episode of clinical mastitis between calving and 100 DIM. The overall crude quarter-level prevalence of infection at dry-off was 19.2%. The most common pathogen isolated from milk samples at dry-off was coagulase-negative Staphylococcus, followed by Aerococcus spp. and other Streptococcus spp. Noninferiority analysis showed no effect of treatment on risk for a cure between dry-off and calving [least squares means (LSM): QT = 93.3%, SP = 92.6%, and TM = 94.0%] and secondary analysis showed no effect of treatment on risk for presence of an IMI at 0 to 6 DIM (LSM: QT = 16.5%, SP = 14.1%, and TM = 16.0%), risk for development of a new IMI between dry-off and 0 to 6 DIM (LSM: QT = 14.8%, SP = 12.3%, and TM = 14.2%), or risk of experiencing a clinical mastitis event between calving and 100 DIM (LSM: QT = 5.3%, SP = 3.8%, and TM = 4.1%). In conclusion, no difference was observed in efficacy among the 3 products evaluated when assessing the aforementioned quarter-level outcomes.

KW - Dry cow mastitis

KW - Dry cow therapy

KW - Quarter-level outcome

UR - http://www.scopus.com/inward/record.url?scp=85027933107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027933107&partnerID=8YFLogxK

U2 - 10.3168/jds.

DO - 10.3168/jds.

M3 - Article

AN - SCOPUS:85027933107

VL - 96

SP - 4419

EP - 4435

JO - Journal of Dairy Science

JF - Journal of Dairy Science

SN - 0022-0302

IS - 7

ER -